---
layout: page
title: Publications
permalink: /pubs/
---

<h2>My Publications</h2>

<h3>Primary Author</h3>
<ul>
  <li><strong>Islam, F.</strong>, et al. (2024). <em>Integrative genetic variation, DNA methylation, and gene expression analysis of escitalopram and aripiprazole treatment outcomes in depression: a CAN-BIND-1 study.</em> <i>Pharmacopsychiatry</i>, 57(5), 232-244.</li>

  <li><strong>Islam, F.</strong>, et al. (2024). <em>Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A CAN-BIND-1 Study.</em> <i>Canadian Journal of Psychiatry</i>, 69(3), 183-195.</li>

  <li><strong>Islam, F.</strong>, et al. (2022). <em>Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.</em> <i>Translational Psychiatry</i>, 12(1), 366.</li>

  <li><strong>Islam, F.</strong>, et al. (2022). <em>Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.</em> <i>Pharmacogenomics Journal</i>, 22(4), 230-240.</li>

  <li><strong>Islam, F.</strong>, et al. (2021). <em>Pharmacogenetics-Guided Advances in Antipsychotic Treatment.</em> <i>Clinical Pharmacology & Therapeutics</i>, 110(3), 582-588.</li>

  <li><strong>Islam, F.</strong>, et al. (2021). <em>Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.</em> <i>Advances in Experimental Medicine and Biology</i>, 1305, 231-255.</li>

  <li><strong>Islam, F.</strong>, et al. (2021). <em>Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia.</em> <i>Journal of Psychopharmacology</i>, 35(1), 31-39.</li>

  <li><strong>Islam, F.</strong>, et al. (2017). <em>Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia.</em> <i>Current Psychiatry Reports</i>, 19(7), 36.</li>

  <li><strong>Islam, F.</strong>, et al. (2017). <em>Inhibition of Wnt signalling dose-dependently impairs the acquisition and expression of amphetamine-induced conditioned place preference.</em> <i>Behavioural Brain Research</i>, 326, 217-225.</li>
</ul>

<h3>Co-Author</h3>
<ul>
  <li>Adams, E., <strong>Islam, F.</strong>, et al. (2025). <em>Effects of Palliative Esophageal External Beam Radiation Therapy in Patients with Stent for Esophageal Cancer: A Retrospective Cohort Study.</em> <i>J Gastrointest Cancer</i>, 56(1), 102.</li>

  <li>Magarbeh, L., <strong>Islam, F.</strong>, et al. (2025). <em>Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report.</em> <i>Canadian Journal of Psychiatry</i>. In press.</li>

  <li>Elsheikh, S., <strong>Islam, F.</strong>, et al. (2024). <em>Genome‐Wide Associations of Cognitive Domains and their Correlation with Polygenic Risk Scores for Antidepressant Response in Late‐Life Depression.</em> <i>Alzheimer's & Dementia</i>, 20(Suppl. 8), e095772.</li>

  <li>Elsheikh, S., <strong>Islam, F.</strong>, et al. (2024). <em>Polygenic score analyses on antidepressant response in Late-life Depression, Results from the IRL-GRey Study.</em> <i>The Pharmacogenomics Journal</i>, 24(6), 38.</li>

  <li>Magarbeh, L., <strong>Islam, F.</strong>, et al. (2023). <em>ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 Study.</em> <i>Clinical Pharmacology & Therapeutics</i>, 114(1), 88-117.</li>

  <li>Marshe, V.S., <strong>Islam, F.</strong>, et al. (2021). <em>Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response.</em> <i>Translational Psychiatry</i>, 11(1), 127.</li>

  <li>Marshe, V.S., <strong>Islam, F.</strong>, et al. (2020). <em>Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine.</em> <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i>, 100, 109867.</li>

  <li>Marshe, V.S., <strong>Islam, F.</strong>, et al. (2020). <em>Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions.</em> <i>American Journal of Geriatric Psychiatry</i>, 28(6), 609-629.</li>
</ul>

<p>See full list and abstracts on <a href="https://scholar.google.com/citations?user=wFqLDl0AAAAJ" target="_blank">Google Scholar</a>.</p>
